Macular Degeneration

Phase III clinical trials of brolucizumab in patients with neovascular age-related macular degeneration

Full article: https://novartis.gcs-web.com/static-files/ad93faf6-c1a9-47a1-899a-547a1b1c66f9

Open pdf (~4.6 mb): Phase III clinical trials of brolucizumab in patients with neovascular age-related macular degeneration

What is brolucizumab (also known as RTH258)?

HAWK and HARRIER

Study Overview

Study Design

Two pivotal trials to test the ecacy and safety of intravitreal injections of brolucizumab 6 mg (HAWK and HARRIER) and brolucizumab 3 mg (HAWK only) versus aflibercept 2 mg in patients with nAMD


Overview: Brolucizumab (RTH258) for the treatment of wet age-related macular degeneration